Reaction
Breast Conserving Surgery reporting signals
As of the last recalculation, Breast Conserving Surgery appears in 505 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is FLUTICASONE FUROATE (PRR 108.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fluticasone Furoate | 30 | 108.5 | 108.7 |
| Theophylline | 28 | 106.2 | 106.5 |
| Theophylline Anhydrous | 29 | 102.2 | 102.5 |
| Mometasone | 31 | 74.1 | 74.3 |
| Moxifloxacin Hydrochloride | 28 | 60.2 | 60.3 |
| Ipratropium Bromide | 47 | 59.8 | 59.8 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 14 | 35.5 | 35.5 |
| Letrozole Tablets | 38 | 35.1 | 35.2 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 31 | 32.8 | 32.8 |
| Letrozole | 42 | 30.6 | 30.6 |
| Pertuzumab | 12 | 18.6 | 18.6 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 3 | 14.6 | 14.6 |
| Bimekizumab | 4 | 7.8 | 7.8 |